California State Teachers Retirement System cut its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 9.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 254,229 shares of the biopharmaceutical company’s stock after selling 26,409 shares during the quarter. California State Teachers Retirement System owned approximately 0.15% of Amicus Therapeutics worth $2,560,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of the stock. Bank of Nova Scotia purchased a new position in Amicus Therapeutics in the 2nd quarter valued at about $1,944,000. Redmile Group LLC lifted its stake in Amicus Therapeutics by 5.9% in the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after buying an additional 668,080 shares in the last quarter. State Street Corp lifted its stake in Amicus Therapeutics by 2.2% in the 2nd quarter. State Street Corp now owns 5,892,564 shares of the biopharmaceutical company’s stock valued at $59,332,000 after buying an additional 125,635 shares in the last quarter. Gotham Asset Management LLC purchased a new position in Amicus Therapeutics in the 2nd quarter valued at about $308,000. Finally, Palo Alto Investors LLC raised its holdings in Amicus Therapeutics by 0.7% in the 2nd quarter. Palo Alto Investors LLC now owns 7,940,788 shares of the biopharmaceutical company’s stock valued at $79,964,000 after acquiring an additional 57,800 shares during the last quarter.
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at $12.89 on Friday. The company has a current ratio of 6.32, a quick ratio of 2.35 and a debt-to-equity ratio of 0.39. Amicus Therapeutics, Inc. has a 1-year low of $4.41 and a 1-year high of $16.60.
Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The firm had revenue of $10.90 million for the quarter, compared to analyst estimates of $9.02 million. Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The firm’s quarterly revenue was up 419.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.33) EPS. analysts expect that Amicus Therapeutics, Inc. will post -1.51 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/11/12/california-state-teachers-retirement-system-decreases-position-in-amicus-therapeutics-inc-fold.html.
In other news, CFO William D. Baird III sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $570,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Daphne Quimi sold 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total transaction of $99,750.00. The disclosure for this sale can be found here. Insiders have sold a total of 628,224 shares of company stock valued at $9,024,003 in the last 90 days. Insiders own 3.40% of the company’s stock.
A number of analysts have commented on the stock. J P Morgan Chase & Co reiterated an “overweight” rating on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Robert W. Baird reiterated an “outperform” rating and issued a $18.00 price objective (up previously from $16.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Chardan Capital reiterated a “buy” rating and issued a $18.50 price objective (up previously from $16.50) on shares of Amicus Therapeutics in a report on Thursday, October 5th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $17.00 price objective on shares of Amicus Therapeutics in a report on Friday, October 6th. Finally, Leerink Swann reiterated a “buy” rating and issued a $20.00 price objective (up previously from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Amicus Therapeutics has a consensus rating of “Buy” and an average target price of $17.81.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.